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In conclusion, we have demonstrated that Tc-99M·DTPA 
allograft scintigraphy is a useful tool in the diagnosis of the 
etiology of renal graft dysfunction in CsA·treated allograft 
recipients. When used in conjunction with clinical assessment 
and CsA blood levels, it forms a pivotal component in a non· 
invasive diagnostic algorithm that is highly sensitive and spe· 
cific for the differentiation of acute cellular rejection and CsNT. 
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FK506 AND PREGNANCY IN LIVER TRANSPLANT PATIENTS 
There have been several reports of successful pregnancy in 
organ transplant patients treated with AZA, steroids, or CsA 
(1,2). However, the use of these immunosuppressive drugs in 
renal transplant patients is often associated with preeclampsia, 
preterm births, and severe intrauterine growth retardation (1). 
Earlier. we have reported pregnancy in liver transplant patients 
treated with AZA or CsA at the University of Pittsburgh 
Medical Center (3). In the present communication, we sum-
marize our recent experience with pregnancy in liver transplant 
patients treated with FK506 as the primary immunosuppressive 
drug. 
At the present time, there are 876 males and 627 female liver 
transplant patients on FK506 immunosuppression at the Uni-
versity of Pittsburgh Medical Center. Nine pregnancies have 
been recorded in 9 of these patients on FK506 therapy. These 
patients received liver transplantation for Caroli's disease (1), 
primary biliary cirrhosis (1), alcoholic cirrhosis (2), cryptogenic 
cirrhosis (2), fulminant hepatic failure (1), autoimmune hepa-
titis (1), or non-A non-B hepatitis (1). The age of the mothers 
ranged from 18 to 35 years. Four of them were primary FK506 
patients and 5 of them were switched to FK506 therapy after 
chronic rejection while on esA. All of the patients received 
FK506 with (n=5) or without steroid (n=4) therapy during the 
entire period of pregnancy. The FK506 doses ranged from 2 mg 
qd to 32 mg bid. Two patients had mild hypertension and 1 
had proteinurea during pregnancy. Six of the 9 patients had 
TABLE 1. Clinical Data in Pregnancies Occurring in Liver Transplant Recipients Treated with FK506 
Time post·OL TX FK506 dosing in 
Case to delivery Duration of FK506 pregnancy (mg) Geltation period Infant birth 
I years I therapy (months) (weeks) weight Before During After 
2.3 8.3 6 bid 10 qd 10qd 36 4 lb 15 oz 
2 1.3 16.5 10qd 10 qd 10qd 35 4 Ib 13 oz 
3 2.8 21 8 bid 8 bid 7 bid 34 4 lb 1 oz 
4 5.75 19 3 bid 3-4 bid 3 bid 34 3 Ib 12.5 0% 
5 1.8 22 2 bid 2-3 bid 3 bid 40 81b 100z 
6 1.6 19.5 24 bid 32 bid 32 bid 37.5 5lb 8.5 oz 
i 0.56 6.75 6 bid 6-7-5 bid 2 qd 22 Unknown 
2 qd 
8 3.6 24 4 bid 5 bid 5 bid 36 Sib 8 0% 
9 1.5 18 5 bid 5 bid 5 bid 37 Sib 6 0% 
OL TX. orthotopic liver transplantation. 
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normal vaginal delivery; 3 patients required cesarean section 
for previous classical cesarean section, placenta abruptio. or 
antepartum hemorrhage. All the patients had normal liver 
function before pregnancy, imd 2 patients who experienced an 
episode of rejection during pregnancy were treated successfully 
with high-dose steroids. Table 1 lists the clinical data on the 
patients and the infants born. None of the babies was consid-
ered small for gestational age, based on the Colorado intrauter-
ine Growth Charts (4). 
Five of the 7 babies for whom potassium levels were available 
had hyperkalemia (range 6.1-10.9 mEq/L) at the time of birth 
that resolved spontaneously within 24-48 hr without any treat-
ment. One baby who was delivered by a patient known to be a 
cocaine addict was hypoxic, tested positive for cocaine. re-
mained in the incubator for 2 weeks, but recovered after that 
time period. One baby who was born to a mother with renal 
impairment during pregnancy was anuric for 36 hr, secondary 
to high FK506 concentrations in the cord, but regained normal 
renal function in 1 week. The only baby that died 2 hr after 
birth was born prematurely (22 weeks) to a 20-year-old patient 
who conceived within a month after transplantation. This 
patient had evidence of CMV in the blood and gastrointestinal 
tract and was treated with ganciclovir. Eight of the 9 babies 
are currently alive and are developing normally. In conclusion, 
liver transplant patients on FK506 appear to have a normal 
course of pregnancy and, in the majority of cases, give birth to 
normal and healthy babies. 
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SUCCESSFUL PREGNANCY IN A PATIENT AFTER LIVER TRANSPLANTATION MAINTAINED ON FK 506 
FK 506 is a novel macrolide immunosuppressant that is 
currently under clinical investigation in patients after solid 
organ transplantation. We here report on a successful preg-
nancy in a patient treated with FK 506. To our knowledge, this 
is the first report of a patient under FK 506 immunosuppression 
who gave birth to a healthy child. 
Case report. A 28-year-old woman was liver grafted for post-
hepatic cirrhosis. After the loss of the tirst graft due to intrac-
table chronic rejection, the second graft again showed signs of 
chronic rejection (Fig. 1). Therefore, FK 506 treatment (0.10 
mg/kg body wt(day; target plasma level < 1.0 ng/ml [1]) was 
initiated, leading to a complete normalization of the patient's 
liver function. 
On week 61. the patient presented in our outpatient clinic 
after having conceived 6 weeks before. After extensive discus-
sions as to whether an abruptio should be performed, it was 
decided not to interrupt the pregnancy. This decision was made 
primarily based on the extensive will of the patient, who was 
fully aware of the risks of this pregnancy. The subsequent 
course of the pregnancy was uneventful: regular sonograms 
showed normal fetal growth. However, on week 28 of pregnancy, 
the patient was readmitted to the hospital with acute graft 
rejection (FK 506 plasma level < 0.05 ng/mll, which was 
successfully treated with bolus steroids and an increase in FK 
506 dosage from 0.10 mg/kg body wt/day to 0.15 mg/kg body 
wt/day. On week 36, after a cesarean section. a healthy male 
newborn of 2860 g was delivered. Apgar scores were normal: no 
congenital abnormalities or birth defects were observed. The 
FK 506 plasma concentration in the placental vein was 0.24 
ng/ml compared with 0.49 ng/ml in the plasma of the mother. 
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FIGURE 1. Clinical course of the patient. Bilirubine as well as ala-
nine transferase levels shown. Abbreviations: ST, BT563 (anti-T cell 
IL-2R MAb); ar, acute rejection: cr, chronic rejection. 
indicating a transplacental transfer of the drug. Three days 
after delivery, the FK 506 plasma concentration in the fetal 
blood was 0.09 ng/ml. and after 1 week, no detectable FK 506 
was present in the blood of the newborn. The mother and the 
healthy newborn were discharged from hospital 12 days after 
delivery. The child is now 12 months old. and in normal 
condition. 
Numerous reports on pregnancies in patients after organ 
transplantation under cyclosporine have been published (re-
